Agreed on all points. One other thing reading the law that has stuck out to me is that it mirrors the worst elements of drug patent regulation. Models only coming into the regs when they pass an arbitrary 100M in development costs means that companies will build on each other just under that cap, or shift money around to license “materially different” models under the cap. Pharma drug makers do the same to tweak old recipes in order to extend monopoly control. Here there’s no basis for whether the law applies when a company strings together 100 1M models into their product or creates 100 99M models that barely differ. It’s both easy to circumvent and unclear when the law will be applied at all.
Agreed on all points. One other thing reading the law that has stuck out to me is that it mirrors the worst elements of drug patent regulation. Models only coming into the regs when they pass an arbitrary 100M in development costs means that companies will build on each other just under that cap, or shift money around to license “materially different” models under the cap. Pharma drug makers do the same to tweak old recipes in order to extend monopoly control. Here there’s no basis for whether the law applies when a company strings together 100 1M models into their product or creates 100 99M models that barely differ. It’s both easy to circumvent and unclear when the law will be applied at all.